Navigation Links
Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member
Date:3/10/2009

SARASOTA, Fla., March 10 /PRNewswire/ -- Lakewood-Amedex, Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics(R), a novel family of synthetic anti-bacterial compounds, announced today the appointment of William J. Robison, a former Pfizer senior executive, to the company's Board of Directors.

Mr. Robison most recently was an Executive Vice President of Pfizer, Inc. until he retired in 2001. He joined Pfizer, Inc. in 1961 and served within Pfizer's pharmaceutical sales organization to become Senior Vice President of Sales for Pfizer Labs. He was subsequently named General Manager for Pratt Pharmaceuticals and in 1992 was named President of Pfizer's Consumer Healthcare Group and made a Pfizer Corporate Officer. In 1996 he joined Pfizer's Corporate Management Committee and was promoted to the position of Executive Vice President and Head of Worldwide Corporate Employee Resources.

Mr. Robison currently serves as a director of several healthcare companies and is also on the Board of Trustees of the University of Louisiana-Monroe. He is a Founding Member of the United States Marine Corps Museum. Mr. Robison received a BS in Mathematics from the University of Louisiana-Monroe.

Steve Parkinson, L-A's President and Chief Executive Officer, commented, "We're delighted to have this highly experienced and respected pharmaceutical professional on our Board. Mr. Robison broadens our existing scientific and medical expertise and he will be especially valuable as we start to develop strategic collaborations with potential large pharmaceutical partners."

Mr. Robison said, "It is a great pleasure to be a part of an exciting and growing company like Lakewood-Amedex. Its broad anti-bacterial and targeted anti-viral products hold great promise for the healthcare industry and could save numerous lives in the future. At the appropriate time we will aggressively seek pharmaceutical companies to work with us in the commercial development of our products."

About Lakewood-Amedex, Inc.

Lakewood-Amedex is a privately held development-stage biopharmaceutical company with a broad patent portfolio of inventions, including, 24 granted and/or issued patents and 45 patent applications covering its proprietary NuBiotics family of anti-microbial products, proven to be effective against a wide range of bacteria, encompassing antibiotic resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas and others, and patents covering certain proprietary products targeting pandemic viral infections including, Epstein Barr Virus (EBV), human and avian influenza, Hepatitis B and C and other clinical indications. The Company anticipates initiating human clinical trials for topical use of its Nu-3 NuBiotics(R) compound in the near future for indications including; diabetic ulcers and other topical infections. Future studies will involve the use of Nu-2(R) to treat broad spectrum antibiotic-resistant bacterial pulmonary and systemic infections. The company is currently conducting a human IRB clinical study to improve treatment of nasopharyngeal carcinoma in Changsha, China. Lakewood-Amedex is headquartered in Sarasota, FL.


'/>"/>
SOURCE Lakewood-Amedex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PURE Bioscience Board Appoints John J. Carbone, MD to Board of Directors
2. China-Biotics, Inc. Appoints New Chief Financial Officer
3. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
4. Mindray Appoints Mr. Ronald Ede as Chief Financial Officer
5. Savara Expands Board of Directors, Appoints Three New Members
6. Informed Medical Communications Appoints New Senior Manager, Strategic Operations
7. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
8. Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development
9. Texcel Medical Appoints Barry Smith as President, CEO
10. SPO Medical Appoints New US Sales Rep Groups
11. iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... BioMedGPS announces expanded coverage of SmartTRAK ... module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and Sealants ... sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market will ...
(Date:10/12/2017)... , ... October 12, 2017 ... ... has launched Rosalind™, the first-ever genomics analysis platform specifically designed for life ... Named in honor of pioneering researcher Rosalind Franklin, who made a major ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... USA (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s ... take place on 7th and 8th June 2018 in San Francisco, CA. The Summit ... as well as several distinguished CEOs, board directors and government officials from around the ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):